Annual Report in NPU II approved
13. 6. 2019
In June 2019, the 2018 report was approved in LQ1605 Translational Medicine (NPU II). We have met all the goals we have set and made considerable progress in our activities. Last year, we reported, among other things, one patent in cooperation with the MAYO Clinic, one utility model, more than 200 publications or seventeen collaborative projects with the application sphere. Foreign experts spent a total of thirty-five man-months on long-term stays here.
Also on the basis of these figures, the Ministry of Education, Youth and Sports stated that the International Clinical Research Center of St. Anne's University Hospital in Brno (FNUSA-ICRC) achieves excellent results of international importance.
The next report will be submitted in January 2020.
Mayor of Brno in FNUSA-ICRC
12. 6. 2019
In mid-June, our center was visited by the Mayor of the City of Brno, Markéta Vaňková. She met the FNUSA-ICRC leadership, headed by our chair Gorazd B. Stokin.
After the introductory presentation of the activities, the tours of selected research teams followed. The Mayor of Brno thus had the opportunity to visit our unique sleep laboratory where we treat patients with sleep disorders, as well as the laboratories of the Biomedical Engineering team, where we presented our new systems for a more accurate diagnosis of cardiac ventricular dyssynchrony and epilepsy. As part of the tour, we also showed the Clinical Pharmacology Unit, where studies of new active substances on volunteers from the Brno population are held for the first time and introduced a new project of research on the use of medical cannabis for the treatment of selected chronic diseases. Representatives of the city of Brno also met with the unique project Kardiovize Brno 2030, a program of cardiovascular prevention in Central and Eastern Europe based on population analysis.
Dozens of Brno Citizens Came to Inform Themselves About Health
11. 6. 2019
Citizens of Brno had the opportunity to visit our exposition in Pohořelec in the city center on the occasion of a long-term exhibition called “Where are you heading, Brno?” which took place as a part of the City Office's project Brno – The Healthy City. Our center presented two projects to the public there. The first was an innovative training program that teaches students and the general public how to save lives when strokes and heart attacks occur. People learn to respond properly to critical situations with simulation scenes that realistically show signs of disease. The second project presented was Kardiovize Brno 2030, a cardiovascular prevention program in Central and Eastern Europe based on population analysis. Dozens of Brno citizens took the opportunity to have their blood pressure measured, tried to measure the strength of their handgrip or the amount of carbon monoxide in the exhalation.
We Attended the Science Fair in Prague
10. 6. 2019
At the beginning of June, we presented our center at the Science Fair organized by the Czech Academy of Sciences. The fair, which took place from 6 to 8 June 2019 in Prague's Letňany, was visited by over 30,000 visitors this year. Representatives of our international center presented the activities of our research teams, not only to the public but also to companies and other scientific institutions and institutes with which cooperation could be established. Thanks to the Kardiovize Brno 2030 project, those interested could measure, for example, the pressure, the strength of the handgrip, the thickness of the blood vessels, the amount of carbon monoxide in the blood, and other indicators of human health.
Faecal microbioma therapy was discussed at the partner forum
24. 5. 2019
FNUSA-ICRC held its 9th FNUSA-ICRC Partner Forum on May 20, focusing on faecal microbiom therapy and its perspectives. The meeting was attended by over 30 participants from healthcare facilities, research centers and companies specializing in the production, development and research of probiotics and prebiotics or microbiome analysis.
Faecal microbioma therapy represents the therapeutic transfer of faeces in native or processed form from donor to recipient. It is done for the treatment of the recipient, high efficacy is especially proven in the problems caused by Clostridium difficilee. However, according to recent studies, this method is also effective in addressing other diseases, such as nonspecific intestinal inflammation, as participants in the forum have shown.
MUDr. Lenka Vojtilová, Ph.D. From the Clinic of Infectious Diseases of the Faculty Hospital Brno introduces the participants with experience with faecal microbiomic therapy in the treatment of clostridial colitis and new promising indications. A comprehensive view of the microbial settlement of the human body and its relation to human health was introduced by Lenka Micenková Ph.D. from Masaryk University in Brno in a lecture entitled "Dynamics of human microbiome in health and illness".
A practical view of this issue, namely experience with the use of faecal filtrates in the treatment of idiopathic intestinal inflammation and pseudomembranous colitis, was presented by Janette Čemická from the Institute of Predictive and Personalized Medicine in Bratislava. In the end, PharmDr. Aleš Franc Ph.D. told participants about methods of enteric and colonial administration of drugs and biological material.
The Partner Forum also included an introduction to the FNUSA-ICRC activities and the presentation of the Clinical Studies Department.
MU Rector's Award was awarded to doc. Paruch
17. 5. 2019
Doc. Mgr. Kamil Paruch, Ph.D., who has been leading the FNUSA-ICRC Medicinal Chemistry research team since 2011, has been awarded the MU Rector's Award for significant creative achievement. Masaryk University is his alma mater, graduated from the Faculty of Science at MU. He then spent 13 years in the United States where he earned a doctorate in organic chemistry at Columbia University. He has also worked on research and development of new drugs in the pharmaceutical company Schering-Plow (Merck since 2009). He returned to Brno in 2009 and since then he has continued to research new organic compounds with targeted biological activity, especially in oncology. This research within FNUSA-ICRC and MU has already brought publications and patents for new drug substances with potential use as drugs for serious diseases. For example, he co-authored the first patent granted to FNUSA-ICRC in 2015: Substituted furo [3,2-b] pyridines for use as a medicament.
The prize was awarded for the development of biologically active compounds with high potential for use in practice.